News

Nearly 2,000 ALS Patients in US Being Treated With Radicava ORS

Nearly 2,000 amyotrophic lateral sclerosis (ALS) patients in the United States have been treated with Radicava ORS (edaravone) since the oral suspension formulation became available there in May, the therapy’s U.S. marketer, Mitsubishi Tanabe Pharma America (MTPA), announced. This formulation is seen to be as equally effective as Radicava, an…

Funding Expands Access to SLS-005 Via Compassionate Use

Seelos Therapeutics is planning to launch an expanded access program (EAP) that gives people with amyotrophic lateral sclerosis (ALS) who are not eligible for clinical trials the opportunity to access the company’s investigational therapy SLS-005. The program will be conducted in collaboration with the Sean M. Healey &…

Cytokinetics Launches 5th Annual Patient Advocacy Grant Program

Cytokinetics has launched its fifth annual Communications Grant Program to support patient advocacy groups working with amyotrophic lateral sclerosis (ALS) and other communities. A total of five $20,000 grants will be given to winning organizations to help them improve their outreach and patient engagement. The deadline for applications…

App Can Help Monitor ALS Progression in Patients From Home

Using a digital tool to assess disease severity remotely is feasible for people with amyotrophic lateral sclerosis (ALS) and may improve patient monitoring between visits to the clinic, a study suggests. The tool makes the revised ALS Functional Rating Scale (ALSFRS-R) available to patients via a computer or mobile…

Relyvrio (AMX0035) Approved in US for ALS Treatment

Note: This story was updated Sept. 30, 2022, to correct the spelling of Albrioza and clarify the FDA advisory committee voted in March that the evidence from CENTAUR was not sufficient to support Relyvrio’s efficacy in ALS. It also added Relyvrio’s list price is set at about $158,000 per year.

Review Finds ‘No Strong Evidence’ Linking Medicines With ALS Risk

There is no compelling evidence to suggest any medication increases the risk of developing amyotrophic lateral sclerosis (ALS), according to a review of published studies. If anything, classes of drugs including anti-hypertensives, cholesterol-lowering statins, aspirin, and oral contraceptives may be associated with a lower risk of ALS, although several…

Early CNM-Au8 Continues to Show Survival Benefits in ALS Patients

Early treatment with CNM-Au8 continues to demonstrate survival benefits in people with amyotrophic lateral sclerosis (ALS) compared with those who started treatment nine months later, according to an update from its developer, Clene Nanomedicine. The updated results come from the RESCUE-ALS Phase 2 trial (NCT04098406) and its open-label…